News

The latest generation technology used by Mevopur additives reduces cycle times by improving rate of crystallization and the crystallization temperature versus conventional technology in homopolymer and random copolymer

Pall’s net earnings were $97.35m for the fourth quarter ended 31 July 2011, compared to $54.96m for the same period in 2010. For the full year ended 31

Currently under development by Viamet Pharma,VT-1161 is intended for the treatment of fungal infections in humans. Viamet president and CEO Robert Schotzinger said in preclinical studies, VT-1161 has

KAI-4169, an intravenous (IV) formulation used in the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease-mineral and bone disorder (CKD-MBD), is in Phase 2 clinical

As per the agreement held during 2009, Pennsaid Viscous Solution is being handled by Nuvo’s licensee – Covidien and it has assumed all responsibility for managing, executing and

The agreement allows ChemPartner to conduct pre-clinical research activities, including target protein preparation and assay system establishment, generation and optimization of lead antibodies, as well as pharmacokinetic and

Perampanel is a highly selective, non-competitive a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor antagonist that has demonstrated anti-epileptic effects in Phase II and III studies. The clinical development plan for

The company has posted net loss of C$15.35m, as compared to net loss of C$1.59m for the year ago period. The basic and fully-diluted net loss per share

The US Food and Drug Administration (FDA) approved Aquoral is indicated for the treatment of xerostomia. PediatRx founder Cameron Durrant said they expect that Aquoral will help further